AbCellera Biologics Inc.

Healthcare

NASDAQ:ABCL · NASDAQ Global Select

Market Cap $1.61B Beta 1.18 P/E (TTM) -11.0

$5.24 -0.57%

-$0.03 today

52W Low $2.75High $6.79

Vol 2.94M · Avg 6.25M

EPS (TTM)-$0.47

Biotechnology

Filings

Ground the analysis in primary documents

Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.

Price History

Dividend-adjusted closing price

Events

Change

+63.75%

Period High

$6.46

Period Low

$2.78

Latest

$5.24

SEC Filings

Recent regulatory filings

No filings found.

Competitors

Peer companies in the same sector

Health

Spyre Therapeutics, Inc.

NASDAQ:SYRE

$4.88B

Vera Therapeutics, Inc.

NASDAQ:VERA

$2.46B

Pharvaris N.V.

NASDAQ:PHVS

$2.15B

Celldex Therapeutics, Inc.

NASDAQ:CLDX

$2.08B

Immunome, Inc.

NASDAQ:IMNM

$1.76B

Nuvation Bio Inc.

NYSE:NUVB

$1.71B

Sionna Therapeutics, Inc.

NASDAQ:SION

$1.62B

Biohaven Ltd.

NYSE:BHVN

$1.19B

Xeris Biopharma Holdings, Inc.

NASDAQ:XERS

$1.17B

Janux Therapeutics, Inc.

NASDAQ:JANX

$826.95M

What is the latest ABCL filing?

The latest filing shown is 8-K dated Jun 12, 2026.

How many recent filings does ABCL have?

Intrinsic Alpha currently shows 20 recent filings for ABCL.

Explore More

Continue the stock analysis

Jump to another research area for this company.

OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.FinancialsReview income statement, balance sheet, and cash flow trends.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.